Join to View Full Profile
800 Rose Street Cc180a Roach Bldg.Uk Hematology ClinicLexington, KY 40536
Phone+1 859-257-6006
Fax+1 859-257-6002
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John Hayslip, MD is an oncologist in Lexington, Kentucky. He is an Associate Professor at University of Kentucky College.
Education & Training
Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2004 - 2007
Summa Health System/NEOMEDResidency, Internal Medicine, 2001 - 2004
Northeast Ohio Medical UniversityClass of 2001- Northeast Ohio Medical UniversityClass of 2001
Publications & Presentations
PubMed
- 2 citationsAuthor Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapyAndrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, V. E. Ivanov
Blood Cancer Journal. 2021-10-26 - 25 citations6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, V. E. Ivanov
Blood Cancer Journal. 2021-10-01 - 50 citationsSafety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.Sven de Vos, John P. Leonard, Jonathan W. Friedberg, Jasmine Zain, Kieron Dunleavy
Leukemia & Lymphoma. 2021-03-21
Press Mentions
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical OncologyJuly 11th, 2025- Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid TumorsJune 25th, 2025
- Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung CancerDecember 18th, 2024
- Join now to see all
